CA2086672A1 - Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof - Google Patents

Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof

Info

Publication number
CA2086672A1
CA2086672A1 CA002086672A CA2086672A CA2086672A1 CA 2086672 A1 CA2086672 A1 CA 2086672A1 CA 002086672 A CA002086672 A CA 002086672A CA 2086672 A CA2086672 A CA 2086672A CA 2086672 A1 CA2086672 A1 CA 2086672A1
Authority
CA
Canada
Prior art keywords
library
bio
oligomers
synthesis
instant invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002086672A
Other languages
French (fr)
Other versions
CA2086672C (en
Inventor
Kit Sang Lam
Sydney E. Salmon
Victor J. Hruby
Evan M. Hersh
Fahad Al-Obeidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2086672A1 publication Critical patent/CA2086672A1/en
Application granted granted Critical
Publication of CA2086672C publication Critical patent/CA2086672C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00585—Parallel processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/0059—Sequential processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00592—Split-and-pool, mix-and-divide processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00702—Processes involving means for analysing and characterising the products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00729—Peptide nucleic acids [PNA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polyethers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

The instant invention provides a library of bio-oligomers of defined size and known composition, in which the library contains all of the possible sequences of the bio-oligomers, and a method of synthesis thereof. The bio-oligomers of the library may be peptides, nucleic acids, or a combination of the foregoing. The instant invention also provides methods to identify bio-oligomers from a library that demonstrate desired characteristics such as binding, bioactivity and catalytic activity. Thus the instant invention provides a unique and powerful method to identify a useful bio-oligomer sequences from a library more quickly than current state-of-the-art technology allows. Effector molecules for use in treatment or diagnosis of disease are also provided.
CA002086672A 1990-07-02 1991-07-01 Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof Expired - Lifetime CA2086672C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54684590A 1990-07-02 1990-07-02
US546,845 1990-07-02
US717,454 1991-06-19
US07/717,454 US5650489A (en) 1990-07-02 1991-06-19 Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
PCT/US1991/004666 WO1992000091A1 (en) 1990-07-02 1991-07-01 Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof

Publications (2)

Publication Number Publication Date
CA2086672A1 true CA2086672A1 (en) 1992-01-03
CA2086672C CA2086672C (en) 2005-04-12

Family

ID=27068387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002086672A Expired - Lifetime CA2086672C (en) 1990-07-02 1991-07-01 Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof

Country Status (23)

Country Link
US (3) US5650489A (en)
EP (1) EP0542770B1 (en)
JP (1) JP3552718B2 (en)
KR (2) KR100222146B1 (en)
AT (1) ATE176330T1 (en)
AU (3) AU659091B2 (en)
CA (1) CA2086672C (en)
CZ (1) CZ289365B6 (en)
DE (1) DE69130828T2 (en)
DK (1) DK0542770T3 (en)
ES (1) ES2126572T3 (en)
FI (1) FI107995B (en)
GR (1) GR3029443T3 (en)
HU (1) HU218007B (en)
IE (1) IE912299A1 (en)
IL (1) IL98682A (en)
MX (1) MX9100052A (en)
NO (1) NO315002B1 (en)
NZ (1) NZ238805A (en)
PL (2) PL169616B1 (en)
RO (1) RO112336B1 (en)
SK (1) SK281490B6 (en)
WO (1) WO1992000091A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847105A (en) * 1994-03-16 1998-12-08 California Institute Of Technology Methods for performing multiple sequential reactions on a matrix
US5958342A (en) * 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device

Families Citing this family (615)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6197529B1 (en) * 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US5646001A (en) * 1991-03-25 1997-07-08 Immunivest Corporation Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
WO1993004204A1 (en) * 1991-08-23 1993-03-04 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
AU2580892A (en) * 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
DK0604552T3 (en) * 1991-09-18 1997-08-04 Affymax Tech Nv Process for the synthesis of different assemblies of oligomers
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US20010021513A1 (en) * 1991-11-21 2001-09-13 Puijk Wouter Cornelis Test device comprising a plate containing a multiplicity of wells with an associated metering device, as well as a kit which comprises these devices and use of the devices
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0638089B2 (en) * 1992-04-15 2008-03-05 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotides
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
WO1994002515A1 (en) * 1992-07-21 1994-02-03 Bunsen Rush Laboratories Inc. Oligomer library formats and methods relating thereto
US5565324A (en) * 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US6503759B1 (en) 1992-10-01 2003-01-07 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
AU686579B2 (en) * 1992-10-01 1998-02-12 Cold Spring Harbor Laboratory Complex combinatorial chemical libraries encoded with tags
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
DE4243770A1 (en) * 1992-12-23 1994-06-30 Behringwerke Ag Process for the production of recombinant and synthetic peptides and their use
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1994020521A1 (en) * 1993-03-12 1994-09-15 Jerini Bio Chemicals Gmbh Process for synthesizing and selecting sequences of covalently bound components
US6864048B2 (en) 1993-04-28 2005-03-08 Affymetrix, Inc. Factorial chemical libraries
PT705279E (en) * 1993-05-27 2003-07-31 Selectide Corp LIBRARIES IN SOLID PHASE CODIFIED, TOPOLOGICALLY SEGREGATED
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
JPH08510325A (en) * 1993-05-28 1996-10-29 カイロン コーポレイション Methods for selecting biologically active peptide sequences
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
NZ268292A (en) * 1993-06-21 1997-09-22 Selectide Corp Solid phase peptide synthesis and supports therefor
EP0788370A4 (en) 1993-07-09 1998-07-08 Smithkline Beecham Corp Cyclic semi-random peptide libraries
AU7193494A (en) * 1993-07-21 1995-02-20 Oxford Glycosystems Ltd Saccharides, their synthesis and use
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
JPH09504424A (en) * 1993-08-13 1997-05-06 エンザイメド，インク． Biocatalytic methods for synthesizing and identifying bioactive components
CN1154640C (en) * 1993-10-01 2004-06-23 纽约市哥伦比亚大学理事 Complex combinatorial chemical libraries encoded with tags
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5503805A (en) * 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US6165778A (en) * 1993-11-02 2000-12-26 Affymax Technologies N.V. Reaction vessel agitation apparatus
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
WO1995016209A1 (en) * 1993-12-09 1995-06-15 Ciba-Geigy Ag Process for the production of combinatorial compound libraries
WO1995016918A1 (en) * 1993-12-15 1995-06-22 Combichem, Inc. Combinatorial libraries and methods for their use
US5587471A (en) * 1994-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Method of making oligonucleotide libraries
CA2180844A1 (en) * 1994-01-13 1995-07-20 W. Clark Still Synthetic receptors, libraries and uses thereof
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5541085A (en) * 1994-02-14 1996-07-30 Zymogenetics, Inc. Method for preparing orphan receptor ligands
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
CA2183428A1 (en) * 1994-03-11 1995-09-14 John J. Baldwin Sulfonamide derivatives and their use
US6936477B2 (en) 1994-04-13 2005-08-30 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5856083A (en) * 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
US5846841A (en) * 1994-05-20 1998-12-08 Selectide Corporation Motif Libraries
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
WO1995034813A1 (en) * 1994-06-14 1995-12-21 Smithkline Beecham Corporation Resins for solid state synthesis
US5663046A (en) * 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
AU2871195A (en) * 1994-06-23 1996-01-19 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
MX9700725A (en) * 1994-07-26 1997-05-31 Scripps Research Inst Soluble combinatorial libraries.
US5939268A (en) * 1994-07-26 1999-08-17 The Scripps Research Institute Combinatorial libraries of molecules and methods for producing same
US5948693A (en) * 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US6558633B1 (en) * 1994-09-21 2003-05-06 Isis Pharmaceuticals, Inc. Chemical reaction apparatus and methods
US5695934A (en) * 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
USRE43097E1 (en) 1994-10-13 2012-01-10 Illumina, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
US6280935B1 (en) 1994-10-13 2001-08-28 Lynx Therapeutics, Inc. Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags
US5846719A (en) 1994-10-13 1998-12-08 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
WO1996012186A1 (en) * 1994-10-14 1996-04-25 Chiron Mimotopes Pty. Ltd. Method and apparatus for efficient mimotope discovery
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5688696A (en) * 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
DE4444260A1 (en) * 1994-12-13 1996-06-20 Hoechst Ag Cyclohexapeptides and their mixtures, process for their preparation and their use
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
GB9502225D0 (en) * 1995-02-04 1995-03-22 Zeneca Ltd Method
WO1996035122A1 (en) * 1995-05-03 1996-11-07 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
US5759865A (en) * 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
AU5871196A (en) * 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6051554A (en) * 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en) * 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
DK0839152T3 (en) * 1995-06-21 2002-07-08 Martek Biosciences Corp Combinatorial libraries of labeled biochemical compounds and processes for their preparation
SE9502286D0 (en) * 1995-06-22 1995-06-22 Pharmacia Ab Process for detection, quantification and / or identification of a peptide
US6579848B1 (en) * 1995-06-23 2003-06-17 The United States Of America As Represented By The Department Of Health And Human Services Depigmenting activity of agouti signal protein and peptides thereof
GB9515070D0 (en) * 1995-07-22 1995-09-20 Zeneca Ltd Label
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
AU728668B2 (en) * 1995-09-11 2001-01-18 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
US6743892B1 (en) 1995-09-11 2004-06-01 La Jolla Cancer Research Foundation Molecules that home to a selected organ in vivo
EP0876611A1 (en) * 1995-09-11 1998-11-11 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
US7026114B1 (en) * 1995-09-13 2006-04-11 Affymetrix, Inc. Methods and compositions for monitoring polymer array synthesis
US6841533B1 (en) 1995-12-07 2005-01-11 Peptor Limited Conformationally constrained backbone cyclized interleukin-6 antagonists
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
ATE240347T1 (en) * 1995-12-18 2003-05-15 Praecis Pharm Inc METHOD FOR DETECTING COMPOUNDS THAT BIND PARTICULAR TARGET MOLECULES
EP0880558A1 (en) * 1996-01-22 1998-12-02 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
DE69722176T2 (en) 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto METHOD FOR SEARCHING TRANSDOMINANT EFFECTOR PEPTIDES AND RNA MOLECULES
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6080719A (en) * 1996-02-23 2000-06-27 Hoechst Aktiengesellschaft Cyclohexapeptides and their mixtures, a process for preparing them, and their use
EP0886681A1 (en) * 1996-03-04 1998-12-30 Genetrace Systems, Inc. Methods of screening nucleic acids using mass spectrometry
DE19610103A1 (en) 1996-03-15 1997-09-18 Basf Ag Cycloalkyl derivatives and their synthesis on solid phase
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
CA2249290A1 (en) * 1996-03-21 1997-09-25 Rui Liang Carbohydrate-based ligand library, assay and method
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6387707B1 (en) 1996-04-25 2002-05-14 Bioarray Solutions Array Cytometry
US7144119B2 (en) 1996-04-25 2006-12-05 Bioarray Solutions Ltd. System and method for programmable illumination pattern generation
DE69737883T2 (en) 1996-04-25 2008-03-06 Bioarray Solutions Ltd. LIGHT-REGULATED, ELECTROKINETIC COMPOSITION OF PARTICLES TO SURFACES
DE19621177A1 (en) 1996-05-24 1997-11-27 Basf Ag Carbohydrate derivatives and their synthesis on solid phase
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6203978B1 (en) * 1996-05-31 2001-03-20 Du Vergier Ltd. Capture of single stranded nucleic acids
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
DE19626762A1 (en) 1996-07-03 1998-01-08 Basf Ag Enzymatically cleavable linker for solid phase synthesis
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5817489A (en) 1996-08-01 1998-10-06 Isis Pharmaceuticals, Inc. Di-nitrogen heterocycle compositions
US5922872A (en) * 1996-08-01 1999-07-13 Isis Pharmaceuticals, Inc. Meta-benzylic and alpha-amido compositions and methods for preparing same
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
US5798035A (en) * 1996-10-03 1998-08-25 Pharmacopeia, Inc. High throughput solid phase chemical synthesis utilizing thin cylindrical reaction vessels useable for biological assay
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6042789A (en) * 1996-10-23 2000-03-28 Glaxo Group Limited System for parallel synthesis of organic compounds
US6149869A (en) * 1996-10-23 2000-11-21 Glaxo Wellcome Inc. Chemical synthesizers
US6025371A (en) * 1996-10-28 2000-02-15 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6413724B1 (en) 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6421612B1 (en) 1996-11-04 2002-07-16 3-Dimensional Pharmaceuticals Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
US6083761A (en) * 1996-12-02 2000-07-04 Glaxo Wellcome Inc. Method and apparatus for transferring and combining reagents
US6054325A (en) * 1996-12-02 2000-04-25 Glaxo Wellcom Inc. Method and apparatus for transferring and combining distinct chemical compositions with reagents
WO1998024760A1 (en) * 1996-12-03 1998-06-11 Graybill Todd L Aminobenzenedicarboxylic acid-based combinatorial libraries
DE69735445T2 (en) 1996-12-10 2006-08-10 Sequenom, Inc., San Diego NON-VOLATILE, NON-VOLATILE MOLECULES FOR MASS MARKING
CA2283474A1 (en) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6045755A (en) * 1997-03-10 2000-04-04 Trega Biosciences,, Inc. Apparatus and method for combinatorial chemistry synthesis
US20030027126A1 (en) 1997-03-14 2003-02-06 Walt David R. Methods for detecting target analytes and enzymatic reactions
US6177464B1 (en) 1997-03-14 2001-01-23 Sepracor, Inc. Ring opening metathesis of alkenes
US7622294B2 (en) 1997-03-14 2009-11-24 Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
JPH10260223A (en) * 1997-03-19 1998-09-29 Fujitsu Ltd Semiconductor inspection device and inspection method using the same
CA2286867A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
US5908960A (en) * 1997-05-07 1999-06-01 Smithkline Beecham Corporation Compounds
US6004823A (en) * 1997-05-07 1999-12-21 Smithkline Beecham Corporation Compounds
GB9710582D0 (en) 1997-05-22 1997-07-16 Oxford Glycosciences Uk Ltd A method for de novo peptide sequence determination
AU756945B2 (en) 1997-05-23 2003-01-30 Bioarray Solutions Ltd Color-encoding and in-situ interrogation of matrix-coupled chemical compounds
WO1998058256A1 (en) * 1997-06-16 1998-12-23 The University Of North Carolina At Chapel Hill PEPTIDO OLIGONUCLEOTIDES (PONs) AND THEIR COMBINATORIAL LIBRARIES
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1387390B1 (en) 1997-06-20 2009-02-18 Bio - Rad Laboratories, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
US5874589A (en) * 1997-07-18 1999-02-23 Glaxo Wellcome, Inc. Methods for synthesizing diverse collections of tetramic acids and derivatives thereof
US6410342B1 (en) * 1997-08-19 2002-06-25 Pharmacopeia, Inc. Method and apparatus for controlled photoelution
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US6960457B1 (en) 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO1999024075A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
US6228579B1 (en) * 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
US6083682A (en) 1997-12-19 2000-07-04 Glaxo Group Limited System and method for solid-phase parallel synthesis of a combinatorial collection of compounds
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US5968361A (en) * 1998-02-24 1999-10-19 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
US6497820B1 (en) 1998-02-03 2002-12-24 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
WO1999043409A1 (en) * 1998-02-27 1999-09-02 Isis Pharmaceuticals, Inc. Hplc fractionation of complex chemical mixtures
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
WO1999047923A2 (en) 1998-03-20 1999-09-23 The Rockefeller University Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
AU3457199A (en) * 1998-03-30 1999-10-18 Arch Development Corporation Methods and compounds for modulating nuclear receptor activity
US6316616B1 (en) 1998-04-02 2001-11-13 President And Fellows Of Harvard College Parallel combinatorial approach to the discovery and optimization of catalysts and uses thereof
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6410687B1 (en) 1998-04-14 2002-06-25 The Regents Of The University Of California Polypeptides for the detection of microtubule depolymerization inhibitors
DE19819889A1 (en) * 1998-05-04 1999-11-11 Fraunhofer Ges Forschung Isolating nucleic acid from samples by binding to array of immobilized, random capture probes
AU746005B2 (en) 1998-05-04 2002-04-11 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Electrical integrated nucleic acid isolation, purification and detection
US6541211B1 (en) 1998-05-20 2003-04-01 Selectide Corporation Apparatus and method for synthesizing combinational libraries
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6872535B2 (en) 1998-05-20 2005-03-29 Aventis Pharmaceuticals Inc. Three-dimensional array of supports for solid-phase parallel synthesis and method of use
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
US6602685B1 (en) 1998-08-17 2003-08-05 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6633543B1 (en) * 1998-08-27 2003-10-14 Intel Corporation Multicast flow control
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
AU1818400A (en) * 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
US20030027214A1 (en) * 1999-02-17 2003-02-06 Kamb Carl Alexander Methods for substrate-ligand interaction screening
EP1185871A4 (en) 1999-06-01 2003-01-15 Caliper Techn Corp Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
IL146798A0 (en) 1999-06-14 2002-07-25 Genentech Inc A structured peptide scaffold for displaying turn libraries on phage
SE9902479D0 (en) * 1999-06-30 1999-06-30 Amersham Pharm Biotech Ab Particle classification as marker
US7742877B1 (en) 1999-07-22 2010-06-22 Becton, Dickinson & Company Methods, apparatus and computer program products for formulating culture media
WO2001012862A2 (en) * 1999-08-18 2001-02-22 Illumina, Inc. Compositions and methods for preparing oligonucleotide solutions
PT1207905E (en) 1999-09-03 2010-12-07 Brigham & Womens Hospital Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
ATE432993T1 (en) * 1999-10-04 2009-06-15 Univ New Jersey Med TAR RNA BINDING PEPTIDES
US6569685B1 (en) * 1999-10-05 2003-05-27 The Molecular Sciences Institute, Inc. Protein fingerprint system and related methods
KR100378252B1 (en) * 1999-11-12 2003-03-29 학교법인 포항공과대학교 Preparation method for synthetic tetrapeptide library by using nitrosulfonylethoxy carbonyl-amino acid
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
CA2396810A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2398961A1 (en) 2000-02-03 2001-08-09 The Regents Of The University Of California Assays for the detection of agents that affect cognition
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
WO2001065462A2 (en) 2000-02-29 2001-09-07 3-Dimensional Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
AU2001247627A1 (en) 2000-03-22 2001-10-03 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing object relationships in a multidimensional space
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7139739B2 (en) 2000-04-03 2006-11-21 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Method, system, and computer program product for representing object relationships in a multidimensional space
US6660229B2 (en) 2000-06-13 2003-12-09 The Trustees Of Boston University Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
JP4744778B2 (en) 2000-06-21 2011-08-10 バイオアレイ ソルーションズ リミテッド Method for analyzing multiple analyte molecules using a specific random particle array
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US6759510B1 (en) * 2000-06-30 2004-07-06 Becton, Dickinson And Company Peptides for use in culture media
US20020019011A1 (en) * 2000-07-07 2002-02-14 Stockwell Brent R. Methods for identifying combinations of entities as therapeutics
US20020051991A1 (en) * 2000-07-11 2002-05-02 Zhi Hong Rapid generation of diverse nucleoside and nucleotide libraries
AU8356201A (en) * 2000-08-11 2002-02-25 Agilix Corp Ultra-sensitive detection systems
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US6963807B2 (en) 2000-09-08 2005-11-08 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
AU2001292142A1 (en) * 2000-09-11 2002-03-22 Affymetrix, Inc. Photocleavable protecting groups
WO2002023202A2 (en) * 2000-09-18 2002-03-21 Genzyme Corporation Method to identify antibody targets based on mass spectrometry (maldi-tof)
WO2002026107A2 (en) 2000-09-25 2002-04-04 The Regents Of The University Of California Model for neurodegenerative diseases involving amyloid accumulation
US20030045005A1 (en) * 2000-10-17 2003-03-06 Michael Seul Light-controlled electrokinetic assembly of particles near surfaces
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
EP1404867B1 (en) * 2000-12-23 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Oligonucleotide transfection screening method
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7054757B2 (en) 2001-01-29 2006-05-30 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Method, system, and computer program product for analyzing combinatorial libraries
DE10106339A1 (en) * 2001-02-09 2002-08-22 Hans-Joachim Mueller Process for high throughput screening of candidate compounds via high throughput direct synthesis of recombinant polypeptides
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US20040219545A1 (en) * 2001-04-13 2004-11-04 Rando Robert F. Methods for identifying small molecules that bind specific rna structural motifs
US20060228730A1 (en) * 2001-04-11 2006-10-12 Rando Robert F Methods for identifying small molecules that bind specific RNA structural motifs
WO2002083837A1 (en) * 2001-04-11 2002-10-24 Ptc Therapeutics, Inc. Methods for identifying small molecules that bind specific rna structural motifs
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
KR20040082273A (en) 2001-05-21 2004-09-24 아클라라 바이오사이언시스 인코퍼레이티드 Methods and compositions for analyzing proteins
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
JP4342934B2 (en) 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Administration of drugs via PEPT-2 transporter
WO2002102820A1 (en) 2001-06-20 2002-12-27 Nuevolution A/S Nucleoside derivatives for library preparation
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
EP2003451B1 (en) 2001-06-26 2012-05-30 Senomyx, Inc. T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
EP1414491A4 (en) 2001-07-09 2005-07-06 Elan Pharm Inc Methods of inhibiting amyloid toxicity
US6800449B1 (en) * 2001-07-13 2004-10-05 Syngenta Participations Ag High throughput functional proteomics
US7413870B2 (en) 2001-08-01 2008-08-19 Rigel Pharmaceuticals, Incorporated SAK: modulation of cellular proliferation for treatment of cancer
US6767731B2 (en) * 2001-08-27 2004-07-27 Intel Corporation Electron induced fluorescent method for nucleic acid sequencing
TW573125B (en) * 2001-08-29 2004-01-21 Combinatorx Inc A screening system for identifying drug-drug interactions and methods of use thereof
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
JP4377689B2 (en) 2001-10-15 2009-12-02 バイオアレイ ソリューションズ リミテッド Combined analysis of polymorphic loci with simultaneous interrogation and enzyme-mediated detection
JP2005522988A (en) 2001-10-25 2005-08-04 メディカル リサーチ カウンシル molecule
US7262269B2 (en) 2001-10-26 2007-08-28 The Regents Of University Of California Method for screening combinational bead library; ligands for cancer cells
US6670142B2 (en) 2001-10-26 2003-12-30 The Regents Of The University Of California Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
AU2002365271B2 (en) * 2001-11-06 2008-12-11 Agilix Corporation Sensitive coded detection systems
ATE434184T1 (en) * 2001-11-20 2009-07-15 Univ Duke INTERFACE BIOMATERIALS
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2002349905A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside libraries and compounds by mcc combinatorial strategies on solid support
US7291456B2 (en) 2002-01-24 2007-11-06 The Regents Of The University Of California Method for determining differences in molecular interactions and for screening a combinatorial library
EP1470551A2 (en) * 2002-01-28 2004-10-27 Burstein Technologies, Inc. Methods and apparatus for logical triggering
CA2471017A1 (en) * 2002-01-31 2003-08-07 Burstein Technologies, Inc. Method for triggering through disc grooves and related optical analysis discs and system
AU2003209054A1 (en) * 2002-02-07 2003-09-02 Discovery Genomics, Inc. Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof
EP1572906A4 (en) 2002-03-04 2008-05-28 Bristol Myers Squibb Co Novel nucleic acid molecules and polypeptides encoding baboon tafi
DK1487978T3 (en) 2002-03-15 2009-03-23 Nuevolution As Improved method for synthesis of template molecules
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7217507B2 (en) 2002-04-15 2007-05-15 The American National Red Cross Method for detecting ligands and targets in a mixture
US20060275753A1 (en) * 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
JP2006506058A (en) * 2002-05-17 2006-02-23 アルフレッド イー． スラネッズ， Process for determining target function and identifying drug leads
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US20100168037A1 (en) * 2002-07-03 2010-07-01 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
AU2003245612A1 (en) 2002-07-11 2004-02-02 The American National Red Cross Method for identifying individual active entities from complex mixtures
US7301006B2 (en) * 2002-07-16 2007-11-27 Wisconsin Alumni Research Foundation Methods and materials for the synthesis of modified peptides
EP1543157A4 (en) * 2002-07-24 2006-11-15 Ptc Therapeutics Inc METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
WO2004013070A2 (en) 2002-08-01 2004-02-12 Nuevolution A/S Multi-step synthesis of templated molecules
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US7157228B2 (en) * 2002-09-09 2007-01-02 Bioarray Solutions Ltd. Genetic analysis and authentication
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
EP1572978A4 (en) * 2002-10-16 2006-05-24 Univ Texas Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
WO2004038415A1 (en) * 2002-10-24 2004-05-06 Biacore Ab Assay with co-immobilized ligands
DK3299463T3 (en) 2002-10-30 2020-12-07 Nuevolution As ENZYMATIC CODING
AU2003298655A1 (en) 2002-11-15 2004-06-15 Bioarray Solutions, Ltd. Analysis, secure access to, and transmission of array images
ES2375958T3 (en) 2002-12-03 2012-03-07 Pathogen Removal And Diagnostic Technologies, Inc. LIGANDOS DE PROTE�? NAS PRIONES AND PROCEDURES OF USE.
US20040185473A1 (en) * 2002-12-17 2004-09-23 Affymetrix, Inc. Releasable polymer arrays
WO2004056994A2 (en) 2002-12-19 2004-07-08 Nuevolution A/S Quasirandom structure and function guided synthesis methods
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
AT413945B (en) * 2003-01-14 2006-07-15 Mattner Frank Dr Use of a compound having a binding capacity to an antibody specific for the natural N-terminal AB42 sequence, for preparing a vaccine for preventing and treating Alzheimer's disease
EP1597395A2 (en) 2003-02-21 2005-11-23 Nuevolution A/S Method for producing second-generation library
GB0305448D0 (en) * 2003-03-10 2003-04-16 Tcp Innovations Ltd Immunoassay
US20040185499A1 (en) * 2003-03-20 2004-09-23 Jolley Michael E. Method of epitope scanning using fluorescence polarization
US20040235053A1 (en) * 2003-03-28 2004-11-25 The Regents Of The University Of California Preparation and application of encoded bead aggregates in combinatorial chemistry
US20040235054A1 (en) * 2003-03-28 2004-11-25 The Regents Of The University Of California Novel encoding method for "one-bead one-compound" combinatorial libraries
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
WO2004087865A2 (en) * 2003-03-31 2004-10-14 The Regents Of The University Of California The preparation and application of ligand-biopolymer conjugates
US20060078893A1 (en) * 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US7510848B2 (en) 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
PL1615992T3 (en) 2003-04-04 2014-03-31 Pathogen Removal And Diagnostic Tech Inc Prion protein binding materials and methods of use
US20040210036A1 (en) * 2003-04-15 2004-10-21 Nanogen, Inc. Peptide substrate libraries
EP1641555B1 (en) 2003-04-30 2020-12-02 Nexus Biosystems, Inc. Multi-well plate providing a high-density storage and assay platform
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
EP1635693A2 (en) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
ATE541052T1 (en) 2003-05-30 2012-01-15 Agensys Inc VARIANTS OF PROSTATE STEM CELL ANTIGEN (PSCA) AND PARTIAL SEQUENCES THEREOF
CA2528508A1 (en) * 2003-06-06 2004-12-16 Combinatorx Incorporated System and method for multidimensional evaluation of combinations of compositions
US7672791B2 (en) * 2003-06-13 2010-03-02 International Business Machines Corporation Method of performing three-dimensional molecular superposition and similarity searches in databases of flexible molecules
US20050118611A1 (en) * 2003-07-24 2005-06-02 Board Of Regents, The University Of Texas System Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
AR046078A1 (en) 2003-08-06 2005-11-23 Senomyx Inc NEW FLAVORS, FLAVORS MODIFIERS, GUSTATIVE SUBSTANCES, TASTE IMPROVERS, GUSTATIVE SUBSTANCES AND / OR IMPROVEMENTS OF UMANI OR SWEET TASTE AND USE OF THE SAME.
DK1670939T3 (en) 2003-09-18 2010-03-01 Nuevolution As Method for obtaining structural information on a coded molecule and method for selecting compounds
WO2005029705A2 (en) 2003-09-18 2005-03-31 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
NZ546072A (en) 2003-09-22 2009-08-28 Bioarray Solutions Ltd Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
WO2005035552A2 (en) * 2003-10-07 2005-04-21 Genzyme Corporation Transducing combinatorial peptide library
WO2005042763A2 (en) 2003-10-28 2005-05-12 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
EP1694859B1 (en) 2003-10-29 2015-01-07 Bioarray Solutions Ltd Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
EP2322637B1 (en) 2003-12-24 2016-05-18 Novo Nordisk A/S Transgenic mouse comprising a polynucleotide encoding human or humanized C5AR
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
PL1734996T3 (en) 2004-04-02 2013-09-30 Univ California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2560513A1 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
AU2005248453B2 (en) * 2004-05-25 2011-09-08 2Curex Identification of compounds modifying a cellular response
EP2583981A3 (en) 2004-05-28 2013-07-31 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
JP4507080B2 (en) * 2004-07-30 2010-07-21 東亞合成株式会社 Antibacterial peptides and their use
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
EP1786430B1 (en) 2004-08-20 2013-04-03 Buck Institute for Age Research Small molecules that replace or agonize p53 function
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US7547775B2 (en) 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
JP2008529035A (en) * 2005-02-03 2008-07-31 パーキンエルマー エルエーエス，インク． Ultra-sensitive detection system using multidimensional signals
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006099386A2 (en) * 2005-03-11 2006-09-21 Massachusetts Institute Of Technology Synthesis and use of colloidal iii-v nanoparticles
EP1863531A1 (en) 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PL1866328T3 (en) 2005-03-22 2011-05-31 Rohto Pharma Peptides which increase collagen or hyaluronic acid production
CN101495645B (en) 2005-03-23 2012-08-22 生物-拉德实验室公司 Method for purifying proteins
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
EP1904093B1 (en) 2005-07-19 2018-06-13 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
KR20080049733A (en) * 2005-08-16 2008-06-04 더 칠드런스 머시 호스피탈 Quantification of microsphere suspension hybridization and uses thereof
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
US7781209B2 (en) 2005-09-25 2010-08-24 Multispan, Inc. GPCR-expressing cell lines
MX2007015931A (en) 2005-10-20 2008-04-22 Senomyx Inc Chimeric human sweet-umami and umami-sweet taste receptors.
US8119572B2 (en) * 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
ES2317819T1 (en) 2005-11-03 2009-05-01 Redpoint Bio Corporation HIGH PERFORMANCE DETECTION TEST FOR THE TRPM5 ION CHANNEL.
BRPI0618338A2 (en) 2005-11-07 2011-08-23 Scripps Resarch Inst use of tissue factor signaling inhibitor, method for identifying an agent that inhibits tf / viia signaling, pharmaceutical compositions and kit
WO2007059064A2 (en) 2005-11-12 2007-05-24 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US7576037B2 (en) 2005-11-18 2009-08-18 Mei Technologies, Inc. Process and apparatus for combinatorial synthesis
ES2901551T3 (en) 2005-12-01 2022-03-22 Nuevolution As Enzymatic Encoding Methods for Efficient Synthesis of Large Libraries
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
US20100137163A1 (en) * 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
WO2007079755A1 (en) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2390666A1 (en) 2006-03-21 2011-11-30 The Regents of The University of California N-Cadherin as target for cancer diagnosis and therapy
MX2008013394A (en) * 2006-04-21 2008-10-31 Wyeth Corp Methods for high-throughput screening of cell lines.
EP3398452A3 (en) 2006-04-21 2018-11-28 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
DK2027158T3 (en) 2006-05-02 2013-01-14 Carviar Aps Method of immunizing a bird species
WO2007129598A1 (en) 2006-05-02 2007-11-15 Teikyo University Method for screening of substance capable of increasing glutathione
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP1865316B1 (en) 2006-06-07 2010-02-24 Nutrinova Nutrition Specialties & Food Ingredients GmbH Screening methods for compounds that modulate the activity of G-protein coupled receptors
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
NZ575090A (en) 2006-09-06 2012-02-24 Univ California Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
WO2008060448A2 (en) 2006-11-10 2008-05-22 Massachusetts Institute Of Technology Small molecule pak inhibitors
WO2008067196A2 (en) 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
EP2114396A4 (en) 2006-12-29 2010-03-10 Salk Inst For Biological Studi Methods for enhancing exercise performance
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
KR101440153B1 (en) * 2007-05-09 2014-09-15 재단법인서울대학교산학협력재단 Process for Identification of Kinase Substrate Specificity by Using Peptide Library
IN2009KN04568A (en) 2007-06-01 2015-08-28 Univ Princeton
EP2164497B1 (en) * 2007-06-11 2018-08-15 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US8163874B2 (en) * 2007-08-06 2012-04-24 The United States Of America, As Represented By The Secretary Of The Navy Beta helical peptide structures stable in aqueous and non-aqueous media and methods for preparing same
ES2477293T3 (en) 2007-08-13 2014-07-16 Baxter International Inc. IVIG modulation of chemokines for the treatment of multiple sclerosis, Alzheimer's disease and Parkinson's disease
US8703161B2 (en) * 2007-08-13 2014-04-22 Elc Management, Llc Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators
KR101599715B1 (en) 2007-08-21 2016-03-08 세노믹스, 인코포레이티드 Human T2R bitterness receptors and uses thereof
WO2009045377A2 (en) 2007-10-01 2009-04-09 Redpoint Bio Corporation A non-desensitizing mutant of the transient receptor potential trpm5 ion channel
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
US8609347B2 (en) 2007-10-22 2013-12-17 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
JP2011514881A (en) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ Use of TAM receptor inhibitors as immunopotentiators and use of TAM activators as immunosuppressants
WO2009079373A2 (en) 2007-12-14 2009-06-25 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
EP2077272A1 (en) * 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
CA2718904C (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9884070B2 (en) 2008-04-21 2018-02-06 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
JP2010043063A (en) 2008-05-09 2010-02-25 Agency For Science Technology & Research Diagnosis and treatment of kawasaki disease
CA2728927C (en) 2008-07-01 2018-02-13 Genocea Biosciences, Inc. Antigen screening system
WO2010009365A1 (en) * 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
WO2010022249A2 (en) 2008-08-20 2010-02-25 Ensemble Discovery Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
CA2738019A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
US20130074214A1 (en) 2008-09-25 2013-03-21 University Of Guelph Nitrogen Responsive Early Nodulin Gene
US10131693B2 (en) 2008-10-20 2018-11-20 Gwangju Institute Of Science And Technology Bipodal-peptide binder
WO2010054189A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
WO2010060599A1 (en) 2008-11-27 2010-06-03 Roche Diagnostics Gmbh Directed synthesis of oligophosphoramidate stereoisomers
ES2779001T3 (en) 2008-12-03 2020-08-13 Scripps Research Inst Stem cell cultures
JP5971948B2 (en) 2008-12-04 2016-08-17 クルナ・インコーポレーテッド Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF
ES2637063T3 (en) 2008-12-04 2017-10-10 Curna, Inc. Treatment of diseases related to tumor suppressor genes by inhibiting the natural antisense transcript to the gene
WO2010065792A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
US20100233172A1 (en) 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
BRPI0922572A2 (en) 2008-12-17 2019-09-24 Scripps Research Inst method for culturing pluripotent cells, pluripotent mammalian cell culture, cell culture medium, isolated pluripotent animal cell, and method for increasing pluripotence of a mammalian cell.
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
CN101768213B (en) 2008-12-30 2012-05-30 中国科学院遗传与发育生物学研究所 Protein related to plant tillering number and coding gene and application thereof
PL2396038T3 (en) 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN101817879A (en) 2009-02-26 2010-09-01 中国科学院遗传与发育生物学研究所 Metallothionein and encoding gene and application thereof
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
CA2755404C (en) 2009-03-17 2020-03-24 Joseph Collard Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
WO2010126670A2 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
CN106237345A (en) 2009-05-06 2016-12-21 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
ES2618572T3 (en) 2009-05-08 2017-06-21 Curna, Inc. Treatment of diseases related to the dystrophin family by inhibiting a natural antisense transcript for the dmd family
JP5922017B2 (en) 2009-05-18 2016-05-24 クルナ・インコーポレーテッド Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
EP2435571B1 (en) 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101801404B1 (en) 2009-06-16 2017-12-20 큐알엔에이, 인크. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
KR101807324B1 (en) 2009-06-26 2017-12-08 큐알엔에이, 인크. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US20120122711A1 (en) * 2009-07-15 2012-05-17 Heath James R Screening of biopolymers
EP2454269A4 (en) * 2009-07-15 2013-03-06 Agency Science Tech & Res Improved screening of biopolymers
KR20120089637A (en) 2009-07-22 2012-08-13 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Differentiation Of Isobaric Aminoic Acid And Other Species
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
CN102712925B (en) 2009-07-24 2017-10-27 库尔纳公司 It is diseases related that SIRTUIN (SIRT) is treated by suppressing SIRTUIN (SIRT) natural antisense transcript
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
EP2464976B1 (en) 2009-08-14 2018-11-21 The Regents of The University of California Methods of diagnosing and treating autism
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011028390A1 (en) 2009-08-24 2011-03-10 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
KR101892760B1 (en) 2009-08-25 2018-08-28 큐알엔에이, 인크. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
CN102791861B (en) 2009-09-25 2018-08-07 库尔纳公司 FLG relevant diseases are treated by adjusting expression and the activity of Filaggrin (FLG)
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
ES2365343B1 (en) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii USE OF CD98 AS AN ENDOMETRIAL RECEPTIVITY MARKER.
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
JP6220126B2 (en) * 2009-11-23 2017-10-25 セルリアン・ファーマ・インコーポレイテッド Polymers based on cyclodextrins for therapeutic delivery
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
JP5982288B2 (en) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
RU2615450C2 (en) 2009-12-29 2017-04-04 Курна, Инк. Treating diseases associated with nuclear respiratory factor 1 (nrf1) by inhibition of natural antisense transcript to nrf1
EP2519632B1 (en) 2009-12-31 2018-04-11 CuRNA, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
JP5963680B2 (en) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
WO2011085347A2 (en) 2010-01-11 2011-07-14 Opko Curna, Llc Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011090949A2 (en) 2010-01-19 2011-07-28 Illumina, Inc. Methods and compositions for processing chemical reactions
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
US9216189B2 (en) 2010-01-25 2015-12-22 Icahn School Of Medicine At Mount Sinai Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
CN102844435B (en) 2010-02-22 2017-05-10 库尔纳公司 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
RU2612884C2 (en) 2010-04-02 2017-03-13 Курна, Инк. Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3
EP2556160A4 (en) 2010-04-09 2013-08-21 Curna Inc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011127933A1 (en) 2010-04-16 2011-10-20 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
KR20180053419A (en) 2010-05-26 2018-05-21 큐알엔에이, 인크. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
EP2400304A1 (en) 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
WO2011163499A2 (en) 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
SG10201506785SA (en) * 2010-08-27 2015-10-29 Agency Science Tech & Res Peptide libraries for screening and other applications
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
EP2643484A4 (en) 2010-11-22 2014-04-16 Univ California Methods of identifying a cellular nascent rna transcript
ES2657590T3 (en) 2010-11-23 2018-03-06 Curna, Inc. Treatment of nanog related diseases by inhibiting the natural antisense transcript to nanog
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
ES2716865T3 (en) 2011-02-18 2019-06-17 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells to a myelinating cell target
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP3450568A3 (en) 2011-03-04 2019-04-24 Intrexon Corporation Vectors conditionally expressing protein
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
EP2694133B1 (en) 2011-04-05 2018-05-23 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
WO2012159089A1 (en) 2011-05-19 2012-11-22 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
RU2620980C2 (en) 2011-06-09 2017-05-30 Курна, Инк. Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
DK2738255T3 (en) 2011-07-29 2017-03-06 Univ Tokushima ERAP1-Derived Peptide and its Use
MX370814B (en) 2011-09-02 2020-01-08 Univ California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof.
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
CN104023760A (en) 2011-10-28 2014-09-03 普莱萨格生命科学公司 Methods for drug delivery
LT2790687T (en) 2011-12-16 2018-12-10 Poseida Therapeutics, Inc. Trpc4 modulators for use in the treatment or prevention of pain
JP6012767B2 (en) 2012-02-07 2016-10-25 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー Substrates, peptide arrays, and methods
CN104302304A (en) 2012-02-16 2015-01-21 宾西法利亚州研究基金会 Modulators of acyl-coa lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
US10105351B2 (en) 2012-03-14 2018-10-23 University Of Central Florida Research Foundation, Inc. Neurofibromatoses therapeutic agents and screening for same
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
US20160054299A9 (en) 2012-04-24 2016-02-25 University Of Miami Perforin 2 defense against invasive and multidrug resistant pathogens
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
EP2855425A4 (en) 2012-06-04 2016-05-18 Scripps Research Inst Novel phenyl glyoxal probes
US20150164800A1 (en) 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
RU2015115631A (en) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния MODULATION IRE1
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
EP2912194B1 (en) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
BR112015013515A2 (en) * 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res methods of generating a mass-defined drug candidate library, and for identifying peptides having a pharmacological property
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
US20140288097A1 (en) 2013-02-07 2014-09-25 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
CA2901029C (en) 2013-02-15 2020-06-16 John J. Rajasekaran Methods and compositions for amplified electrochemiluminescence detection
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US20160083698A1 (en) 2013-04-19 2016-03-24 The Regents Of The University Of California Lone star virus
US10626178B2 (en) 2013-08-21 2020-04-21 Raz Yirmiya Treatment of mood and stress related disorders
WO2015025323A1 (en) 2013-08-21 2015-02-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mood and stress related disorders
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
WO2015089338A2 (en) 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
CN106572650B (en) 2014-06-10 2021-08-31 生物马特里卡公司 Stabilization of thrombocytes at ambient temperature
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EA201792214A1 (en) 2015-04-10 2018-01-31 Араксис Фарма Ллк COMPOUNDS OF SUBSTITUTE QUINAZOLINE
ES2856880T3 (en) 2015-04-15 2021-09-28 Araxes Pharma Llc KRAS Condensed Tricyclic Inhibitors and Methods of Using Them
AU2016250849A1 (en) 2015-04-24 2017-11-02 Agena Bioscience, Inc. Multiplex methods for detection and quantification of minor variants
US10233489B2 (en) 2015-04-24 2019-03-19 Agena Bioscience, Inc. Multiplexed method for the identification and quantitation of minor alleles and polymorphisms
WO2016195982A2 (en) 2015-06-01 2016-12-08 The Penn State Research Foundation Hepatitis b virus capsid assembly
US20160370380A1 (en) * 2015-06-16 2016-12-22 Pharmaseq, Inc. Combinatorial antibody diagnostic
WO2016209772A2 (en) 2015-06-22 2016-12-29 Proteovista Llc Snp arrays
EP3314260B1 (en) 2015-06-24 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
AU2016368265B2 (en) 2015-12-08 2021-10-28 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
EP3413921A4 (en) 2016-02-09 2019-08-14 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10726944B2 (en) 2016-10-04 2020-07-28 International Business Machines Corporation Recommending novel reactants to synthesize chemical products
JP2019534260A (en) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Heterocyclic compounds as inhibitors of RAS and methods of use thereof
RU2019121922A (en) 2016-12-15 2021-01-18 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (en) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 Condensed miscellaneous-Heterobicyclic compounds and its application method
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11771703B2 (en) 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
WO2018175505A1 (en) 2017-03-20 2018-09-27 Genocea Biosciences, Inc. Treatment methods
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
BR112019024674A2 (en) 2017-05-25 2020-06-16 Araxes Pharma Llc COVALENT KRAS INHIBITORS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
TW201906832A (en) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 Compounds for cancer treatment and methods of use thereof
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
ES2947336T3 (en) 2017-09-01 2023-08-07 Univ Johns Hopkins Targeted epigenetic therapy for hereditary aortic aneurysm
EP3692073A4 (en) 2017-10-03 2021-05-26 Cedars-Sinai Medical Center Methods for targeting the immune checkpoint pd1 pathway for treating pulmonary fibrosis
WO2019090242A1 (en) 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
US20220412979A1 (en) 2018-10-29 2022-12-29 Genocea Biosciences, Inc. Treatment methods
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
EP3917571A4 (en) 2019-01-31 2022-10-12 Agency For Science, Technology And Research Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
RU2699563C1 (en) * 2019-05-29 2019-09-06 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ) Modified synthetic analogue of natural opioid peptide enkephalin
DE102020202529A1 (en) * 2020-02-27 2021-09-02 Robert Bosch Gesellschaft mit beschränkter Haftung Method for identifying a combination of active ingredients
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023086969A2 (en) 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4392997A (en) * 1981-07-06 1983-07-12 Northwestern University Antigenic peptide compounds
US4618598A (en) * 1982-04-12 1986-10-21 Duke University Method of regulating hormone function or release
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4555101A (en) * 1984-03-13 1985-11-26 Stobb, Inc. Method and apparatus for separating signatures from a stack
US4590003A (en) * 1984-03-23 1986-05-20 Oncogen Platelet related growth regulator
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
WO1986000991A1 (en) * 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4705777A (en) * 1985-02-25 1987-11-10 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
US4863857A (en) * 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
WO1986006487A1 (en) * 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
CS256960B1 (en) * 1985-11-16 1988-04-15 Viktor Krchnak Peptides with properties of antigenic determinants and method of their production
US4780421A (en) * 1986-04-03 1988-10-25 Sclavo Inc. Cleavable labels for use in binding assays
US4837304A (en) * 1987-05-22 1989-06-06 Merck & Co., Inc. Inhibitor of ribonucleotide reductase
DE3855890T2 (en) * 1987-10-13 1998-02-12 Terrapin Tech Inc METHOD FOR PRODUCING IMUNODIAGNOSIS
AU628812B2 (en) * 1988-03-24 1992-09-24 Telik, Inc. Paralog affinity chromatography
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
JP3042626B2 (en) * 1988-05-24 2000-05-15 ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュング エムベーハー（ゲーベーエフ） Determination of DNA base sequence using oligonucleotide bank
US4988625A (en) * 1988-11-09 1991-01-29 Merck & Co., Inc. Method for determining the functionalization of a solid support
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847105A (en) * 1994-03-16 1998-12-08 California Institute Of Technology Methods for performing multiple sequential reactions on a matrix
US6015880A (en) * 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5958342A (en) * 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device

Also Published As

Publication number Publication date
AU8238591A (en) 1992-01-23
SK281490B6 (en) 2001-04-09
US5858670A (en) 1999-01-12
NZ238805A (en) 1994-07-26
ATE176330T1 (en) 1999-02-15
JPH06500308A (en) 1994-01-13
PL168354B1 (en) 1996-02-29
NO315002B1 (en) 2003-06-23
US5650489A (en) 1997-07-22
GR3029443T3 (en) 1999-05-28
RO112336B1 (en) 1997-08-29
DE69130828D1 (en) 1999-03-11
KR100222146B1 (en) 1999-10-01
JP3552718B2 (en) 2004-08-11
IL98682A0 (en) 1992-07-15
AU2845495A (en) 1996-05-16
CZ407392A3 (en) 1993-10-13
EP0542770A4 (en) 1993-09-15
WO1992000091A1 (en) 1992-01-09
IE912299A1 (en) 1992-01-15
EP0542770A1 (en) 1993-05-26
HU9204179D0 (en) 1993-04-28
HUT63576A (en) 1993-09-28
AU659091B2 (en) 1995-05-11
MX9100052A (en) 1992-02-28
EP0542770B1 (en) 1999-01-27
FI107995B (en) 2001-11-15
CA2086672C (en) 2005-04-12
DK0542770T3 (en) 1999-09-13
HU218007B (en) 2000-05-28
IL98682A (en) 1997-02-18
AU683762B2 (en) 1997-11-20
NO930011L (en) 1993-02-22
SK407392A3 (en) 1994-08-10
ES2126572T3 (en) 1999-04-01
KR100245767B1 (en) 2000-03-15
CZ289365B6 (en) 2002-01-16
DE69130828T2 (en) 1999-06-17
NO930011D0 (en) 1993-01-04
PL169616B1 (en) 1996-08-30
FI925986A0 (en) 1992-12-31
US5510240A (en) 1996-04-23
AU2836995A (en) 1995-12-07
FI925986A (en) 1992-12-31

Similar Documents

Publication Publication Date Title
CA2086672A1 (en) Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
RU94000061A (en) Cholesterol esters and unsaturated fatty acids, the method of treatment and the pharmaceutical or cosmetic composition
DE3886845D1 (en) High-strength, heat-resistant aluminum alloys and processes for producing articles from these alloys.
CA2223694A1 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
CA2056357A1 (en) Process for the preparation of a ligand-receptor complex
DE68913466T2 (en) Sputtering target and process for its production.
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
EP1564290A3 (en) Nucleic acid ligands of tissue targets
EP2283855A3 (en) Polypeptides et polynucleotides de phorphorymonas gingivalis
DE59401009D1 (en) Process for the preparation of 1,1,1,3,3-pentafluoropropane
CA2145969A1 (en) Transcription factor aprf
DE69603530D1 (en) Process for the preparation of 1,1-difluoroethane
DE3874150D1 (en) ITEMS FROM ALUMINUM-SILICON ALLOY AND METHOD FOR PRODUCING THE SAME.
DE69006820D1 (en) Process for the preparation of 1,1-dichlorotetrafluoroethane.
Lam et al. Method of screening a peptide library
DE69001427T2 (en) Process for the preparation of 1,6-hexenedienoic acids from butenediol.
DE68913888D1 (en) Process for the preparation of 3,5-dialkyl-4-hydroxybenzyl-substituted aromatics.
DE68922361D1 (en) Process for the preparation of 2,6-naphthalenedicarboxylic acid.
CA2262884A1 (en) Egf-like factor from chromaffin granules and glia cell-derived neurotrophic factor with survival-promoting activity on daergic neurons
Rosin Blah-blah.
CA2143442A1 (en) Dorsal tissue affecting factor and compositions
DE69001426T2 (en) Process for the preparation of 1,6-hexenedienoic acids.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20110701